A carregar...
Publicação
Sensitizing methicillin-resistant Staphylococcus aureus (MRSA) to cefuroxime
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 627.54 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Methicillin-resistant Staphylococcus aureus (MRSA) strains are a major challenge for clinicians due, in part, to their resistance to most β-lactams, the first-line treatment for methicillin-susceptible S. aureus. A phenotype termed “NaHCO3-responsiveness” has been identified, wherein many clinical MRSA isolates are rendered susceptible to standard-of-care β-lactams in the presence of physiologically relevant concentrations of NaHCO3, in vitro and ex vivo; moreover, such “NaHCO3-responsive” isolates can be effectively cleared by β-lactams from target tissues in experimental infective endocarditis (IE). One mechanistic impact of NaHCO3 exposure on NaHCO3responsive MRSA is to repress WTA synthesis. This NaHCO3 effect mimics the phenotype of tarO-deficient MRSA, including sensitization to the PBP2-targeting β-lactam, cefuroxime (CFX). Herein, we further investigated the impacts of NaHCO3 exposure on CFX susceptibility in the presence and absence of a WTA synthesis inhibitor, ticlopidine (TCP), in a collection of clinical MRSA isolates from skin and soft tissue infections (SSTI) and bloodstream infections (BSI). NaHCO3 and/or TCP enhanced susceptibility to CFX in vitro, by both minimum inhibitor concentration (MIC) and time-kill assays, as well as in an ex vivo simulated endocarditis vegetations (SEV) model, in NaHCO3-responsive MRSA. Furthermore, in experimental IE (presumably in the presence of endogenous NaHCO3), pre-exposure to TCP prior to infection sensitized the NaHCO3-responsive MRSA strain (but not the non-responsive strain) to enhanced clearances by CFX in target tissues. These data support the notion that NaHCO3 is acting similarly to WTA synthesis inhibitors, and that such inhibitors have potential translational applications in the treatment of certain MRSA strains in conjunction with specific β-lactam agents.
Descrição
Funding Information: This work was supported by the following grant from the National Institutes of Health: 1RO1-AI146078 (to A.S.B.). Conceptualization: S.C.E., A.S.B., R.A.P.; methodology: S.C.E., W.E.R., W.A.; formal analysis: S.C.E., W.E.R., W.A.; investigation: S.C.E., W.E.R., W.A., S.H.F., S.L.M., A.M.E.; resources: A.S.B.; writing – original draft: S.C.E., A.S.B.; writing – review and editing: S.C.E., A.S.B., R.A.P., H.F.C.; supervision: A.S.B.; project administration: A.S.B.; funding acquisition: A.S.B. Funder Grant(s) Author(s) HHS | National Institutes of Health (NIH) AI146078 Arnold S. Bayer Funding Information: This work was supported by the following grant from the National Institutes of Health: 1RO1-AI146078 (to A.S.B.). Publisher Copyright: Copyright © 2024 Ersoy et al.
Palavras-chave
experimental infective endocarditis (IE) methicillin-resistant Staphylococcus aureus (MRSA) NaHCOresponsive penicillin-binding proteins (PBPs) wall teichoic acid (WTA) synthesis β-lactams Pharmacology Pharmacology (medical) Infectious Diseases SDG 3 - Good Health and Well-being